Paul J. Hastings

CIK: 0001309702

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (44.4%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (55.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

NKTX

Nkarta, Inc.

DirectorOfficer

ENGN

enGene Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

NKTX
Nkarta, Inc.
Jun 18, 2026
Sale(S)
Direct
1.8K shares at avg. $2.71$5K
ENGN
enGene Therapeutics Inc.
Jun 16, 2026
Award(A)
Stock Option (Right to Buy)
Direct
31K shares-
NKTX
Nkarta, Inc.
Jan 15, 2026
Sale(S)
Direct
26K shares at avg. $2.07$54K
NKTX
Nkarta, Inc.
Jan 6, 2026
Award(A)
Direct
94K shares-
NKTX
Nkarta, Inc.
Jun 18, 2025
Sale(S)
Direct
1.8K shares at avg. $1.79$3K
ENGN
enGene Holdings Inc.
Jun 16, 2025
Award(A)
Stock Option (Right to Buy)
Direct
22.5K shares-
NKTX
Nkarta, Inc.
Jun 5, 2025
Award(A)
Stock Option (right to buy)
Direct
377K shares-
NKTX
Nkarta, Inc.
Jan 15, 2025
Sale(S)
Direct
17.4K shares at avg. $2.20$38K
NKTX
Nkarta, Inc.
Jan 3, 2025
Award(A)
Direct
94.5K shares-

		Type	Shares	Price		Ownership
Jun 18, 2026	NKTX Nkarta, Inc.	Sale(S)	1,776	$2.71	$4,813	Direct
Jun 16, 2026	ENGN enGene Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	31,000	-	-	Direct
Jan 15, 2026	NKTX Nkarta, Inc.	Sale(S)	26,046	$2.07	$53,915	Direct
Jan 6, 2026	NKTX Nkarta, Inc.	Award(A)	94,000	-	$0	Direct
Jun 18, 2025	NKTX Nkarta, Inc.	Sale(S)	1,790	$1.79	$3,204	Direct
Jun 16, 2025	ENGN enGene Holdings Inc.	Award(A) Stock Option (Right to Buy)	22,500	-	-	Direct
Jun 5, 2025	NKTX Nkarta, Inc.	Award(A) Stock Option (right to buy)	377,000	-	-	Direct
Jan 15, 2025	NKTX Nkarta, Inc.	Sale(S)	17,378	$2.20	$38,232	Direct
Jan 3, 2025	NKTX Nkarta, Inc.	Award(A)	94,500	-	$0	Direct

1-9 of 9 transactions

About HASTINGS PAUL J

HASTINGS PAUL J (SEC CIK 0001309702) files insider reports with the SEC as Chief Executive Officer of Nkarta, Inc. (NKTX) and Director of enGene Therapeutics Inc. (ENGN).

Signal8 holds 9 ownership filings by HASTINGS PAUL J, all Form 4s, filed between Jan 7, 2025 and Jun 22, 2026. Those filings report 9 transactions, from Jan 3, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on HASTINGS PAUL J's filings is in SAINT-LAURENT.

Recent filings by HASTINGS PAUL J

Jun 18, 2026: Open-market sale of NKTX shares (Form 4, code S).
Jun 16, 2026: Grant or award of ENGN derivative securities (Form 4, code A).
Jan 15, 2026: Open-market sale of NKTX shares (Form 4, code S).
Jan 6, 2026: Grant or award of NKTX shares (Form 4, code A).
Jun 18, 2025: Open-market sale of NKTX shares (Form 4, code S).

Other insiders filing for Nkarta, Inc. (NKTX)

How to read Form 4 transaction codes